Drug firm Dr Reddy’s Laboratories has shifted focus of its drug discovery to new segments, including dermatology and pain management, from cardiac diseases and diabetes due to high costs involved for the latter. The company is eying at a product which will directly address this segment of post surgical infections to improve its performance in India and Europe. Biosimilars is one such major area company is seeking for its growth from 2016 to 2020.
The company could not afford for some of the trials like CVDs as it required at least 30,000 patients.
Dr Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |